{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:58:42Z","timestamp":1790283522017,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.07.018","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:58:49Z","timestamp":1790279929000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Morbidit\u00e9 sexuelle\/intime sous tamoxif\u00e8ne et risque de fragilisation de l\u2019adh\u00e9sion th\u00e9rapeutique chez les femmes non m\u00e9nopaus\u00e9es atteintes d\u2019un cancer du sein RH+\u00a0: un d\u00e9terminant sous-estim\u00e9 et potentiellement modifiable"],"prefix":"10.1016","author":[{"given":"Flora","family":"Ancelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bondil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9869","key":"10.1016\/j.bulcan.2026.07.018_bib0005","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10\u00a0years versus stopping at 5\u00a0years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bulcan.2026.07.018_bib0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.2017.75.8995","article-title":"Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline","volume":"36","author":"Carter","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.018_bib0015","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","article-title":"Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer","volume":"21","author":"Partridge","year":"2003","journal-title":"J Clin Oncol"},{"issue":"12\u00a0Suppl. 1","key":"10.1016\/j.bulcan.2026.07.018_bib0020","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S0007-4551(20)30046-1","article-title":"Gestion des effets secondaires de l\u2019hormonoth\u00e9rapie du cancer du sein chez la femme jeune","volume":"106","author":"Saghatchian","year":"2019","journal-title":"Bull Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.018_bib0025","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bcp.14172","article-title":"The ABC taxonomy for medication adherence translated into French and German","volume":"86","author":"Haag","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.018_bib0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4048\/jbc.2023.26.e22","article-title":"Investigation of factors affecting adherence to adjuvant hormone therapy in early-stage breast cancer patients: a comprehensive systematic review","volume":"26","author":"Yang","year":"2023","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.bulcan.2026.07.018_bib0035","doi-asserted-by":"crossref","first-page":"104510","DOI":"10.1016\/j.breast.2025.104510","article-title":"Improving medication adherence to endocrine therapy in breast cancer patients: a mixed-methods systematic review of effective communication strategies for healthcare providers","volume":"82","author":"Smits","year":"2025","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.bulcan.2026.07.018_bib0040","first-page":"949","article-title":"Nurses\u2019 attitudes toward addressing sexual health in their professional practice within cancer care: a Danish cross-sectional study","volume":"33","author":"Mortensen","year":"2025","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.018_bib0045","first-page":"332","article-title":"Sexual dysfunction in women with breast cancer: a systematic review","volume":"33","author":"Rodrigues-Machado","year":"2025","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2026.07.018_bib0050","series-title":"Pr\u00e9servation de la sant\u00e9 sexuelle et cancer\u00a0\u2013\u00a0th\u00e9saurus","author":"Association francophone pour les soins oncologiques de support (AFSOS)","year":"2021"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.018_bib0055","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11764-017-0674-4","article-title":"Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?","volume":"12","author":"Ekinci","year":"2018","journal-title":"J Cancer Surviv"},{"issue":"12","key":"10.1016\/j.bulcan.2026.07.018_bib0060","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0007-4551(20)30050-3","article-title":"Tol\u00e9rance du tamoxif\u00e8ne en traitement adjuvant et devenir lointain de 55\u00a0femmes non m\u00e9nopaus\u00e9es suivies \u00e0 l\u2019Institut de canc\u00e9rologie de Lorraine, pour un cancer du sein","volume":"106","author":"Sebaoun","year":"2019","journal-title":"Bull Cancer"},{"issue":"28","key":"10.1016\/j.bulcan.2026.07.018_bib0065","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.23.00697","article-title":"A systematic review and meta-analysis of interventions to promote adjuvant endocrine therapy adherence among breast cancer survivors","volume":"41","author":"Bright","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.018_bib0070","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s11764-023-01513-y","article-title":"Interventions to improve oral endocrine therapy adherence in breast cancer patients","volume":"19","author":"Ganna","year":"2025","journal-title":"J Cancer Surviv"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.018_bib0075","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/0092623X.2019.1676853","article-title":"Sexual health needs: how do breast cancer patients and their partners want information?","volume":"46","author":"Albers","year":"2020","journal-title":"J Sex Marital Ther"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.018_bib0080","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12282-018-0927-8","article-title":"Intimacy and sexuality in women with breast cancer: professional guidance needed","volume":"26","author":"Den Ouden","year":"2019","journal-title":"Breast Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2026.07.018_bib0085","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/07357907.2022.2066112","article-title":"Breast cancer patients\u2019 experience and wishes regarding communication on sexual health: the BEROSE study","volume":"40","author":"Aupomerol","year":"2022","journal-title":"Cancer Invest"},{"issue":"9","key":"10.1016\/j.bulcan.2026.07.018_bib0090","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.pec.2020.03.029","article-title":"Communication about sexual health in breast cancer: what can we learn from patients\u2019 self-report and clinic dialogue?","volume":"103","author":"Reese","year":"2020","journal-title":"Patient Educ Couns"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.018_bib0095","doi-asserted-by":"crossref","first-page":"102236","DOI":"10.1016\/j.esmoop.2024.102236","article-title":"Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes","volume":"9","author":"Franzoi","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.bulcan.2026.07.018_bib0100","doi-asserted-by":"crossref","first-page":"e303","DOI":"10.1016\/S1470-2045(20)30666-5","article-title":"Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer","volume":"22","author":"Franzoi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.018_bib0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jsxmed\/qdae007","article-title":"Communication and sexual function and frequency in breast cancer patients 2\u00a0years after diagnosis: results from the VICAN 2\u00a0study","volume":"21","author":"Almont","year":"2024","journal-title":"J Sex Med"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.018_bib0110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s11764-023-01511-0","article-title":"Silent suffering: the impact of sexual health challenges on patient-clinician communication and adherence to adjuvant endocrine therapy among Black women with early-stage breast cancer","volume":"19","author":"Anderson","year":"2025","journal-title":"J Cancer Surviv"},{"issue":"16\u00a0Suppl","key":"10.1016\/j.bulcan.2026.07.018_bib0115","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2024.42.16_suppl.536","article-title":"Sexual health and therapy adherence of hormone-sensitive breast cancer survivors on maintenance endocrine therapy: the SHE-CAN project in Toronto, Canada","volume":"42","author":"Remtulla Tharani","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.07.018_bib0120","unstructured":"Aptecar L. \u00c9valuation de la qualit\u00e9 globale et sexuelle durant la premi\u00e8re ann\u00e9e d\u2019hormonoth\u00e9rapie chez les patientes atteintes d\u2019un cancer du sein [m\u00e9moire]. 2019. Disponible\u00a0: https:\/\/dumas.ccsd.cnrs.fr\/dumas-02865071."},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.018_bib0125","first-page":"114","article-title":"Self-image and sexuality issues among young women with breast cancer: practical recommendations","volume":"69","author":"Hungr","year":"2017","journal-title":"Rev Invest Clin"},{"issue":"24","key":"10.1016\/j.bulcan.2026.07.018_bib0130","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.19.01758","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.07.018_bib0135","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1007\/s11764-023-01407-z","article-title":"Prevalence of sexual dysfunction after breast cancer compared to controls, a study from CONSTANCES cohort","volume":"18","author":"Mangiardi-Veltin","year":"2024","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.bulcan.2026.07.018_bib0140","doi-asserted-by":"crossref","DOI":"10.1007\/s11764-025-01827-z","article-title":"Assessing the perceived usefulness and impact of a sexual health consultation service for female patients in a comprehensive cancer center","author":"Aupomerol","year":"2025","journal-title":"J Cancer Surviv"},{"issue":"15","key":"10.1016\/j.bulcan.2026.07.018_bib0145","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.3390\/cancers15153860","article-title":"Supportive care: the \u201ckeystone\u201d of modern oncology practice","volume":"15","author":"Scott\u00e9","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.018_bib0150","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1186\/s12913-022-08243-4","article-title":"Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy","volume":"22","author":"Green","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.018_bib0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.sexol.2021.06.002","article-title":"Cancer et sexualit\u00e9\u00a0: que doit savoir le professionnel de sant\u00e9 non sp\u00e9cialis\u00e9\u00a0?","volume":"30","author":"Bondil","year":"2021","journal-title":"Sexologies"},{"issue":"5","key":"10.1016\/j.bulcan.2026.07.018_bib0160","first-page":"394","article-title":"Syndrome g\u00e9nito-urinaire de la m\u00e9nopause (SGUM). RPC les femmes m\u00e9nopaus\u00e9es du CNGOF et du GEMVi","volume":"49","author":"Hock\u00e9","year":"2021","journal-title":"Gynecol Obstet Fertil Senol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126004005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126004005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:58:54Z","timestamp":1790279934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126004005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S0007455126004005"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.018","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morbidit\u00e9 sexuelle\/intime sous tamoxif\u00e8ne et risque de fragilisation de l\u2019adh\u00e9sion th\u00e9rapeutique chez les femmes non m\u00e9nopaus\u00e9es atteintes d\u2019un cancer du sein RH+\u00a0: un d\u00e9terminant sous-estim\u00e9 et potentiellement modifiable","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}